|
|
xv | |
About the editors |
|
xxi | |
Preface |
|
xxv | |
|
Chapter 1 Genomics and psychiatry: a historical overview |
|
|
1 | (16) |
|
|
|
|
1 | (1) |
|
|
2 | (1) |
|
|
3 | (1) |
|
|
3 | (1) |
|
|
4 | (1) |
|
|
5 | (1) |
|
|
6 | (1) |
|
|
7 | (1) |
|
|
8 | (1) |
|
|
8 | (1) |
|
|
9 | (1) |
|
|
9 | (1) |
|
Genome-wide association studies |
|
|
9 | (1) |
|
|
10 | (1) |
|
Lessons learned from history |
|
|
11 | (2) |
|
|
13 | (4) |
|
Chapter 2 Schizophrenia genomics |
|
|
17 | (26) |
|
|
|
|
|
|
|
17 | (1) |
|
Schizophrenia heritability |
|
|
18 | (1) |
|
Molecular genetics before genomics |
|
|
18 | (1) |
|
|
19 | (1) |
|
Genome-wide association studies |
|
|
19 | (2) |
|
Rare structural risk variants |
|
|
21 | (2) |
|
Genome sequencing studies |
|
|
23 | (2) |
|
Lessons learned from schizophrenia genomics |
|
|
25 | (1) |
|
|
25 | (1) |
|
|
26 | (1) |
|
|
27 | (1) |
|
Molecular mechanisms and pathways |
|
|
28 | (1) |
|
|
29 | (1) |
|
|
30 | (1) |
|
|
31 | (1) |
|
|
32 | (11) |
|
Chapter 3 Genetics of bipolar disorder |
|
|
43 | (20) |
|
|
|
|
|
43 | (1) |
|
Family and adoption studies |
|
|
43 | (1) |
|
|
44 | (1) |
|
|
44 | (1) |
|
Linkage and candidate gene studies |
|
|
45 | (1) |
|
Genome-wide association studies |
|
|
45 | (1) |
|
|
45 | (1) |
|
Genetic architecture of BD |
|
|
46 | (1) |
|
|
46 | (2) |
|
Genetic overlap between BD and other traits and disorders |
|
|
48 | (2) |
|
Polygenic analytical approaches |
|
|
50 | (2) |
|
From genetic loci to disease mechanisms |
|
|
52 | (1) |
|
Rare genetic variants in BD |
|
|
53 | (1) |
|
Potential clinical implications of BD genetics |
|
|
53 | (1) |
|
|
54 | (1) |
|
|
55 | (1) |
|
Competing financial interests |
|
|
55 | (1) |
|
|
55 | (8) |
|
Chapter 4 Genetics of depression |
|
|
63 | (4) |
|
|
Genetic factors affecting the onset of depression |
|
|
63 | (2) |
|
|
65 | (1) |
|
|
66 | (1) |
|
Chapter 5 Genetics of personality disorders |
|
|
67 | (18) |
|
|
|
67 | (1) |
|
International classification of personality disorders |
|
|
67 | (2) |
|
Heritability of personality disorders |
|
|
69 | (2) |
|
First evidence of genetic predisposition in personality disorders |
|
|
71 | (1) |
|
|
71 | (2) |
|
Meta-analysis of candidate gene studies in personality disorders |
|
|
73 | (1) |
|
Interaction between gene and environmental factors in personality disorders |
|
|
74 | (1) |
|
Comorbid disorders and traits, environment, and genetic factors in personality disorders |
|
|
75 | (1) |
|
Genome-wide associations studies in personality disorders |
|
|
76 | (1) |
|
Neuroticism and personality phenotypes |
|
|
76 | (3) |
|
|
79 | (1) |
|
|
80 | (1) |
|
GWAS in borderline personality disorder |
|
|
80 | (1) |
|
|
81 | (1) |
|
|
82 | (3) |
|
Chapter 6 Genomics and epigenomics of anxiety and obsessive-compulsive disorders |
|
|
85 | (20) |
|
|
|
|
Clinical genetics, molecular genetics, gene-environment interactions and epigenetics of anxiety disorders |
|
|
85 | (1) |
|
Epidemiology and clinical genetics |
|
|
85 | (1) |
|
|
86 | (3) |
|
Gene--environment interactions and epigenetics |
|
|
89 | (3) |
|
Epidemiology, clinical genetics, molecular genetics, gene-environment interactions and epigenetics of obsessive-compulsive disorders |
|
|
92 | (1) |
|
|
92 | (1) |
|
Gene--environment interactions and epigenetics |
|
|
92 | (1) |
|
Therapy (epi)genetics of anxiety and OCDs |
|
|
93 | (1) |
|
|
94 | (1) |
|
|
95 | (10) |
|
Chapter 7 Neurogenetics of alcohol use disorder a subset of reward deficiency syndrome: candidate genes to be or not to be? |
|
|
105 | (56) |
|
|
|
|
|
|
|
|
|
|
Introduction--a historical overview |
|
|
105 | (1) |
|
The genetics of alcoholism |
|
|
106 | (1) |
|
Finding the first alcohol gene |
|
|
107 | (2) |
|
Understanding polygenic inheritance of alcoholism and links to opioids |
|
|
109 | (1) |
|
GARS case--controls and targeted endophenotypes for alcohol abuse and alcoholism |
|
|
110 | (34) |
|
Importance of genome wide association studies: convergence to candidates |
|
|
144 | (1) |
|
|
144 | (2) |
|
|
146 | (1) |
|
|
146 | (1) |
|
|
146 | (1) |
|
|
147 | (1) |
|
|
147 | (14) |
|
Chapter 8 Pharmacogenomics and antipsychotics: efficacy and adverse drug reactions |
|
|
161 | (28) |
|
Evangelia Eirini Tsermpini |
|
|
|
|
|
|
161 | (1) |
|
Pharmacogenetics of antipsychotics metabolizing enzymes and drug targets |
|
|
162 | (1) |
|
Pharmacogenes involved in antipsychotic metabolism and transport |
|
|
163 | (3) |
|
Pharmacogenomics of antipsychotic efficacy |
|
|
166 | (1) |
|
Candidate gene studies of treatment response |
|
|
166 | (1) |
|
Genomic studies of antipsychotic efficacy |
|
|
167 | (2) |
|
Epigenetics of treatment response |
|
|
169 | (1) |
|
Pharmacogenetics of antipsychotic-induced adverse drug reactions |
|
|
170 | (1) |
|
|
171 | (1) |
|
Clozapine-induced agranulocytosis and neutropenia |
|
|
172 | (1) |
|
Antipsychotic-induced weight gain |
|
|
173 | (1) |
|
Pharmacogenetic-based treatment guidelines for antipsychotics |
|
|
174 | (2) |
|
|
176 | (1) |
|
Clinical implementation studies |
|
|
177 | (1) |
|
|
178 | (1) |
|
|
179 | (10) |
|
Chapter 9 Pharmacogenomics and antidepressants: efficacy and adverse drug reactions |
|
|
189 | (14) |
|
|
|
Financial disclosures (last 3 years) |
|
|
189 | (1) |
|
|
190 | (1) |
|
Safety versus efficacy, and pharmacokinetics versus pharmacodynamics |
|
|
190 | (5) |
|
Pharmacokinetic pharmacogenomics and efficacy |
|
|
195 | (1) |
|
Pharmacodynamic pharmacogenomics and efficacy |
|
|
196 | (1) |
|
Antidepressant efficacy trials using combinatorial pharmacogenomic panels |
|
|
197 | (2) |
|
Clinical implications and future directions |
|
|
199 | (1) |
|
|
199 | (1) |
|
|
200 | (3) |
|
Chapter 10 Pharmacogenomics and mood stabilizers: efficacy and adverse drug reactions |
|
|
203 | (20) |
|
|
|
|
203 | (1) |
|
Pharmacogenomics of lithium |
|
|
204 | (1) |
|
Lithium response: candidate-gene studies |
|
|
204 | (6) |
|
Lithium response: from candidate gene to genome-wide association studies |
|
|
210 | (4) |
|
Lithium-induced adverse drug reactions |
|
|
214 | (1) |
|
Pharmacogenomics of other mood stabilizers |
|
|
214 | (1) |
|
Response to other mood stabilizers |
|
|
214 | (1) |
|
Adverse drug reactions induced by other mood stabilizers |
|
|
215 | (1) |
|
|
215 | (1) |
|
|
216 | (7) |
|
Chapter 11 Balancing prevention and respect: the ethical stakes of a psychiatric genomics lens for mental disorder and intellectual disability |
|
|
223 | (18) |
|
|
|
223 | (3) |
|
Conceptual framing and ethical orientation: points of divergence |
|
|
226 | (3) |
|
Challenging projections of suffering |
|
|
229 | (5) |
|
Responding to the ethical stakes |
|
|
234 | (2) |
|
|
236 | (1) |
|
|
237 | (1) |
|
|
237 | (4) |
|
Chapter 12 Genetic animal models for psychiatric disorders |
|
|
241 | (28) |
|
|
|
|
Genetic evidence, epidemiology, and genetic animal models |
|
|
241 | (1) |
|
Identifying candidate genes for modeling |
|
|
241 | (1) |
|
Modeling candidate genes in animal systems |
|
|
242 | (1) |
|
|
243 | (1) |
|
Disrupted-in-schizophrenia 1 (DISCI) |
|
|
243 | (2) |
|
Neuregulin-1 (NRG1) and receptor tyrosine-protein kinase erbB-4 (ErbB4) |
|
|
245 | (2) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
248 | (1) |
|
|
248 | (3) |
|
|
251 | (1) |
|
|
252 | (1) |
|
Glycogen synthase kinase 3 |
|
|
253 | (1) |
|
Major depressive disorder |
|
|
253 | (1) |
|
|
253 | (2) |
|
Stress-related genes in depression |
|
|
255 | (1) |
|
|
256 | (1) |
|
|
256 | (13) |
|
Chapter 13 Psychiatric genomics: brain pathophysiology and genetic factors |
|
|
269 | (20) |
|
|
|
|
|
|
|
|
269 | (1) |
|
Autism spectrum disorders |
|
|
269 | (1) |
|
Pathophysiology of autism spectrum disorders |
|
|
270 | (1) |
|
Genetics of autism spectrum disorders |
|
|
271 | (1) |
|
Attention deficit hyperactivity disorder |
|
|
271 | (1) |
|
Pathophysiology of attention deficit hyperactivity disorder |
|
|
272 | (1) |
|
Genetics of attention deficit hyperactivity disorder |
|
|
272 | (1) |
|
Antisocial personality disorder |
|
|
273 | (1) |
|
Pathophysiology of antisocial personality disorder |
|
|
273 | (1) |
|
Genetics of antisocial personality disorder |
|
|
273 | (1) |
|
|
274 | (1) |
|
Pathophysiology of schizophrenia |
|
|
274 | (1) |
|
Major depressive disorder |
|
|
275 | (1) |
|
Pathophysiology of major depressive disorder |
|
|
276 | (1) |
|
Genetics of major depressive disorder |
|
|
277 | (1) |
|
|
277 | (1) |
|
Pathophysiology of bipolar disorder |
|
|
277 | (1) |
|
Genetics of bipolar disorder |
|
|
278 | (1) |
|
Generalized anxiety disorder |
|
|
278 | (1) |
|
Pathophysiology of generalized anxiety disorder |
|
|
278 | (1) |
|
Genetics of generalized anxiety disorder |
|
|
279 | (1) |
|
|
279 | (1) |
|
Pathophysiology of panic disorder |
|
|
280 | (1) |
|
Genetics of panic disorder |
|
|
280 | (1) |
|
|
280 | (1) |
|
|
281 | (8) |
|
Chapter 14 Integration with systems biology approaches and -omics data to characterize risk variation |
|
|
289 | (28) |
|
|
|
|
|
289 | (1) |
|
Functional annotation of noncoding regions |
|
|
289 | (1) |
|
Annotations from experimental data |
|
|
290 | (1) |
|
|
291 | (1) |
|
Context-specific genetic regulation |
|
|
292 | (1) |
|
|
293 | (1) |
|
|
294 | (3) |
|
|
297 | (2) |
|
|
299 | (3) |
|
Annotation of variants to gene pathways |
|
|
302 | (1) |
|
|
302 | (1) |
|
|
303 | (1) |
|
|
304 | (1) |
|
Network-based variant interpretation |
|
|
304 | (2) |
|
Conclusion/Future Directions |
|
|
306 | (1) |
|
|
306 | (11) |
|
Chapter 15 Usage of biobank data for psychiatric genomics and promotion of precision psychiatry |
|
|
317 | (24) |
|
|
|
|
317 | (4) |
|
Psychiatric genomics in a biobank setting |
|
|
321 | (1) |
|
Contextualizing the limitations of biobanks for psychiatric genomics |
|
|
321 | (2) |
|
|
323 | (2) |
|
Evaluation of algorithmic phenotyping |
|
|
325 | (1) |
|
|
325 | (1) |
|
|
326 | (2) |
|
Major impact of biobanks on psychiatric genomics research |
|
|
328 | (1) |
|
Applications to genome-wide association studies |
|
|
328 | (1) |
|
Phenome-wide and lab-wide association studies |
|
|
329 | (1) |
|
Practicing the implementation of precision psychiatry |
|
|
330 | (2) |
|
|
332 | (1) |
|
|
333 | (1) |
|
|
334 | (7) |
|
Chapter 16 Shared heritability among psychiatric disorders and traits |
|
|
341 | (20) |
|
|
|
|
|
|
|
|
|
341 | (2) |
|
Shared heritability, genetic overlap, and pleiotropy |
|
|
343 | (2) |
|
Evaluating genetic overlap |
|
|
345 | (1) |
|
|
345 | (1) |
|
|
346 | (1) |
|
Overlap beyond genetic correlation |
|
|
347 | (3) |
|
Identifying specific shared loci |
|
|
350 | (1) |
|
|
351 | (1) |
|
Rare variant genetic overlap |
|
|
352 | (1) |
|
Implications for psychiatry |
|
|
353 | (1) |
|
|
353 | (1) |
|
|
354 | (1) |
|
Competing financial interests |
|
|
354 | (1) |
|
|
354 | (7) |
|
Chapter 17 Endophenotypes in psychiatric genomics: a selective review of their status and a call to action |
|
|
361 | (17) |
|
|
|
|
|
Introduction and context: The endophenotype construct |
|
|
361 | (1) |
|
Progress in identifying genomic endophenotypes |
|
|
362 | (1) |
|
Schizophrenia endophenotypes |
|
|
362 | (2) |
|
Mood disorder endophenotypes |
|
|
364 | (1) |
|
Transdiagnostic endophenotypes |
|
|
364 | (1) |
|
Animal studies of endophenotypes |
|
|
365 | (1) |
|
Questioning the clinical utility of endophenotypes |
|
|
366 | (1) |
|
Advancing a dimensional understanding of psychopathology |
|
|
367 | (4) |
|
Clinical translation of endophenotypes |
|
|
371 | (1) |
|
The role of nongenomic studies |
|
|
371 | (1) |
|
Endophenotypes and clinical prediction |
|
|
372 | (1) |
|
Race and racism in psychiatric genomics |
|
|
373 | (5) |
Conclusions |
|
378 | (1) |
Acknowledgment |
|
378 | (1) |
References |
|
379 | (6) |
Index |
|
385 | |